Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings

World Journal of Surgical Oncology

Isamu Koyama¹  Kiyoka Hara¹  Yohei Morita¹  Hiroka Kondo¹  Asami Suzuki¹  Toshimasa Ishii¹  Shigeki Yamaguchi¹  Jo Tashiro¹ 

[1] Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Yamane, Hidaka-shi, Saitama 350-1298, Japan

关键词: Tegafur plus leucovorin;    Capecitabine;    Overall survival;    Relapse-free survival;    Colorectal cancer;    Oral adjuvant chemotherapy;   

Others  :  811784
DOI  :  10.1186/1477-7819-12-145

 received in 2014-01-04, accepted in 2014-04-29,  发布年份 2014

【 摘 要 】

Background

Cancer patients not admissible for adjuvant chemotherapy are generally at high risk of considerably inferior prognosis. The aim of this retrospective study was to evaluate poorer survival without administration of oral adjuvant chemotherapy of stage III colon cancer patients in clinical settings.

Methods

Between April 2007 and September 2011, 259 patients with stage III colon cancer who underwent curative surgery were retrospectively assigned to the adjuvant chemotherapy group of 171 patients (66%) and the surgery alone group of 88 patients. Oral fluorouracil (5-FU) derivatives used in adjuvant chemotherapy, such as oral uracil and tegafur plus leucovorin (UFT/LV) or capecitabine, were the most commonly used.

Results

The 3-year relapse-free survival (RFS) rates were 74.9% for all cases, 58.3% for the surgery alone group, and 83.4% for the adjuvant chemotherapy group (P = 0.0001). The chemotherapy group was associated with a dramatic improvement in survival for stage IIIB (surgery alone 57.7% versus adjuvant chemotherapy 83.9%; P = 0.0001) and stage IIIC (surgery alone 18.2% versus adjuvant chemotherapy 57.3%; P = 0.006) patients. There was a significant difference in the overall recurrence rate between groups (surgery alone 35.2% versus adjuvant chemotherapy 18.1%; P = 0.002). Multivariate analysis identified adjuvant therapy as an independent predictive factor of reduced recurrence (hazard ratio (HR): 3.231; P = 0.004) and improved RFS (HR: 2.653; P = 0.001).

Conclusion

In clinical settings, adjuvant therapy was the only significant prognostic factor of survival. Since many patients prefer not to receive chemotherapy, it is critical to inform stage III colon cancer patients that chemotherapy raises their chances of survival by three-fold compared with curative surgery alone.

【 授权许可】

   
2014 Tashiro et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322(6):352-358.
• [2]NIH consensus conference: adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264(11):1444-1450.
• [3]Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11(10):1879-1887.
• [4]O’Connell MJ, Wolmark N, Yothers G, Haile S, Colangelo L, Petrelli N: Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03. J Clin Oncol 2005, 23(1):248.
• [5]Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17(11):3553-3559.
• [6]Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994, 12(11):2296-2300.
• [7]Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP: A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer Adjuvant therapy for patients with colon and rectal cancer. Cancer 1995, 75(3):782-785.
• [8]Meguro M, Furuhata T, Okita K, Nishidate T, Ishiyama G, Iwayama Y, Kimura Y, Mizuguchi T, Hirata K: Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients. Int J Clin Oncol 2009, 14(5):402-407.
• [9]Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004, 22(10):1797-1806.
• [10]Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
• [11]Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C, X-ACT Study Group: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003, 14(12):1735-1743.
• [12]Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, Kameoka S, Saito Y, Takahashi K, Hase K, Oya M, Maeda K, Hirai T, Kameyama M, Shirouzu K, Muto T: Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 2007, 141(1):67-75.
• [13]Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: Colon and rectum. In AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.
• [14]Mochizuki I, Takiuchi H, Ikejiri K, Nakamoto Y, Kinugasa Y, Takagane A, Endo T, Shinozaki H, Takii Y, Takahashi Y, Mochizuki H, Kotake K, Kameoka S, Takahashi K, Watanabe T, Watanabe M, Boku N, Tomita N, Matsubara Y, Sugihara K: Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. Br J Cancer 2012, 106(7):1268-1273.
• [15]Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N: Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007, 25(4):424-430.
• [16]Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Can 1998, 34(8):1274-1281.
• [17]Mjör IA: Practice-based dental research. J Oral Rehabil 2007, 34(12):913-920.
• [18]Tashiro J, Yamaguchi S, Ishii T, Sato T, Suwa H, Okada I, Kondo H, Miyazawa M, Shinozuka N, Koyama I: A comparative study on the short-term clinical outcomes of laparoscopic versus open Hartmann’s procedure for high risk patients in colorectal cancer. Hepatogastroenterology 2012, 59(117):1403-1407.
• [19]Schrag D, Cramer LD, Bach PB, Begg CB: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001, 93(11):850-857.
• [20]Jessup JM, McGinnis LS, Steele GD Jr, Menck HR, Winchester DP: The national cancer data base report on colon cancer. Cancer 1996, 78(4):918-926.
• [21]Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345(15):1091-1097.
• [22]Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI: Survival associated with 5-fluorouracil–based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002, 136(5):349-357.
• [23]Fisher M, Yang LX: Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 2002, 22(3):1737-1754.